The app for independent voices
Where is $500M for Pandemic Preparedness going? A sober take on HHS terminating 22 mRNA projects with BARDA... Meet the new Anthony Fauci wielding the old beta-propiolactone. By Sasha Latypova (08/08/25)
On August 5, 2025, HHS issued the following press release (quoted below):
HHS Winds Down mRNA Vaccine Development Under BARDA. hhs.gov/press-room/hhs-…
WASHINGTON, D.C. — The U.S. Department of Health and Human Services (HHS) today announced the beginning of a coordinated wind-down of its mRNA vaccine development activities under the Biomedical Advanced Research and Development Authority (BARDA), including the cancellation and de-scoping of various contracts and solicitations. The decision follows a comprehensive review of mRNA-related investments initiated during the COVID-19 public health emergency.
“We reviewed the science, listened to the experts, and acted,” said HHS Secretary Robert F. Kennedy, Jr. “BARDA is terminating 22 mRNA vaccine development investments because the data (zenodo.org/records/1578…) show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu. We’re shifting that funding toward safer, broader vaccine platforms that remain effective even as viruses mutate.”
The wind-down affects a range of programs including:
Termination of contracts with Emory University and Tiba Biotech.
De-scoping of mRNA-related work in existing contracts with Luminary Labs, ModeX, and Seqirus.
Rejection or cancellation of multiple pre-award solicitations, including proposals from Pfizer, Sanofi Pasteur, CSL Seqirus, Gritstone, and others, as part of BARDA’s Rapid Response Partnership Vehicle (RRPV) and VITAL Hub.
Restructuring of collaborations with DoD-JPEO, affecting nucleic acid-based vaccine projects with AAHI, AstraZeneca, HDT Bio, and Moderna/UTMB.
While some final-stage contracts (e.g., Arcturus and Amplitude) will be allowed to run their course to preserve prior taxpayer investment, no new mRNA-based projects will be initiated. HHS has also instructed its partner, Global Health Investment Corporation (GHIC), which manages BARDA Ventures, to cease all mRNA-based equity investments. In total, this affects 22 projects worth nearly $500 million. Other uses of mRNA technology within the department are not impacted by this announcement.
“Let me be absolutely clear: HHS supports safe, effective vaccines for every American who wants them. That’s why we’re moving beyond the limitations of mRNA and investing in better solutions,” said Secretary Kennedy.
The move signals a broader shift in federal vaccine development priorities. Going forward, BARDA will focus on platforms with stronger safety records and transparent clinical and manufacturing data practices. Technologies that were funded during the emergency phase but failed to meet current scientific standards will be phased out in favor of evidence-based, ethically grounded solutions – like whole-virus vaccines and novel platforms.
__________
Many in the health freedom movement celebrated these actions. But Sasha Latypova — in her inimitable and snarky way — was far from celebratory. She dug deeper to follow the money, the players, and the projects that HHS is exploring as “platforms with stronger safety records and transparent clinical and manufacturing data practices.”
We encourage you to read her article for a perspective that you won’t hear anywhere else (the article isn’t long and only a bit technical). Latypova’s research is always impeccable, so it’s worth exploring her work even if you vehemently disagree with her conclusions.
In case you’re wondering, Latypova is no fan of the MAHA movement, recent actions from HHS Director RFK Jr., or the pandemic handling by Trump 1.0 and 2.0. Read the article, the Substack comments, and then draw your own conclusions. We doubt the issues are black and white, since gray-water politics infuses them all.
ED NOTE
As former faithful to allopathic medicine and “vaccines,” we began exploring COVID, COVID "vaccines," and all other vaccines almost five years ago.
Since then, we’ve pivoted 180-degrees to support NO vaccines, healthy lifestyle, supporting the immune system as naturally as possible (vaccines destroy the immune system, turns out), good food, fresh air, adequate quality sleep (which we fail to achieve on every level!😩), regular exercise, and early supportive treatment in case one gets sick.
COVID had early treatments available all along, but such treatments were suppressed by media, pharmaceutical/biomedical complex, and government. Turns out that most "infectious" diseases are victims of the same suppressed information.__________
Boring, Sanitized Summary (ChatGPT, edited; images from article)
Latypova criticizes the U.S. Department of Health and Human Services’ (HHS) decision—announced alongside Robert F. Kennedy Jr.—to cancel several mRNA vaccine projects and pivot toward a “safer” universal vaccine platform based on beta-propiolactone (BPL)-inactivated whole-virus technology.
Latypova challenges the narrative of improved safety, highlights potential toxicity concerns of BPL and its degradation products, and questions the financial transparency and potential commercial benefits behind the initiative.
She also critiques the use of fetal cell lines in vaccine production and considers the public health establishment’s messaging as self-serving and misleading.
Background & Context
HHS announced cancellations of multiple mRNA-based vaccine contracts, including:
Moderna: $176M for H5N1 avian flu vaccine.
Emory University: inhaled mRNA/CRISPR antivirals for respiratory viruses.
Tiba Biotech: $749,999 for RNAi-based influenza therapeutics.
Remaining funds ($500M) are redirected toward a universal, non-mRNA vaccine platform.
Pivot to “Safer” Platforms
Focus on whole-virus, BPL-inactivated vaccines targeting broad viral families.
NIH developing candidates BPL-1357 and BPL-24910 to cover influenza and coronaviruses.
Ownership model: government-developed and funded, claimed to avoid commercial conflicts (yet conflicts abound).
Criticism of Safety Claims
BPL Concerns:
Classified as a carcinogen (IARC) and genotoxic agent.
Historically restricted in sterilization due to toxicity.
Claimed safety after degradation to β-hydroxypropionic acid—but no injection safety data exists.
Safety assumptions are untested and misleading.
Commercial & Political Skepticism
Questions potential licensing to major pharma companies for large-scale manufacturing.
Notes bipartisan cooperation in the project’s development.
Cites controversial key figures such as acting Director of NIAID Jeffrey Taubenberger
He was responsible for sequencing THE SPANISH FLU VIRUS!!!
Holds patent for “Broadly Protective Influenza Vaccine Comprising a Cocktail of Inactivated Avian Influenza Viruses”
Ethical & Biological Concerns
Use of fetal-derived cell lines WI38 and MRC5 in production.
Retention of all in-process chemicals in final vaccines.
Lack of liability and minimal regulatory oversight.
Reference:
Material Safety Data Sheet for Beta-Propiolactone: tinyurl.com/5n6pbtr3
More references and links within the article
